Evogene (NASDAQ:EVGN) Stock Price Crosses Above 50-Day Moving Average of $0.98

Evogene Ltd. (NASDAQ:EVGNGet Rating)’s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.98 and traded as high as $1.07. Evogene shares last traded at $1.01, with a volume of 49,012 shares changing hands.

Analyst Ratings Changes

Separately, Roth Capital cut their price target on Evogene from $6.00 to $3.00 in a report on Friday, September 2nd.

Evogene Stock Performance

The stock has a market capitalization of $26.01 million, a P/E ratio of -1.29 and a beta of 1.23. The stock has a 50-day simple moving average of $0.98 and a 200 day simple moving average of $1.03.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Sigma Planning Corp lifted its stake in shares of Evogene by 88.0% in the 1st quarter. Sigma Planning Corp now owns 31,410 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 14,700 shares during the period. Virtu Financial LLC acquired a new stake in Evogene during the 1st quarter worth $48,000. Vident Investment Advisory LLC raised its stake in Evogene by 68.5% during the 1st quarter. Vident Investment Advisory LLC now owns 83,868 shares of the biotechnology company’s stock worth $109,000 after buying an additional 34,082 shares during the period. Bank of America Corp DE raised its stake in shares of Evogene by 49.7% in the 1st quarter. Bank of America Corp DE now owns 204,521 shares of the biotechnology company’s stock valued at $265,000 after purchasing an additional 67,867 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Evogene by 51.8% in the 1st quarter. Renaissance Technologies LLC now owns 459,081 shares of the biotechnology company’s stock valued at $597,000 after purchasing an additional 156,716 shares during the period.

Evogene Company Profile

(Get Rating)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements.

Featured Articles

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.